Does marijuana rescheduling to Schedule III mean employers must stop drug testing for THC?

No. The April 2026 DOJ order does not change federal workplace drug testing requirements. DOT-regulated employers must continue testing for marijuana, and non-regulated employers retain discretion over their own policies unless a state law restricts testing.

Can employers still fire an employee for a positive marijuana test after rescheduling?

In federally regulated workplaces, yes—a positive THC test remains a violation. For non-regulated employers, the answer depends on applicable state law. Over 20 states now limit adverse action based solely on a positive marijuana test for off-duty use.

Do employers need to accommodate medical marijuana use in the workplace?

Federal law does not currently require accommodation of on-the-job marijuana use. However, employers in states with medical marijuana employment protections may need to engage in an interactive process for off-duty medical use, particularly for non-safety-sensitive roles.

What policy language should employers update after the DOJ marijuana rescheduling order?

Employers should remove or revise references to marijuana as a 'Schedule I substance' or 'illegal drug' where that language conflicts with its new federal classification. Policies should instead reference 'prohibited substances' or 'substances that impair job performance' and specify testing authority under company policy and applicable law.

When does the broader marijuana rescheduling hearing take place?

The DEA has scheduled an expedited administrative hearing beginning June 29, 2026, to address broader rescheduling of recreational marijuana. Employers should monitor developments closely, as the outcome may further affect workplace drug policies.

Marijuana Rescheduled to Schedule III: What Employers Must Do With Their Drug-Free Workplace Policies Now

On April 23, 2026, the U.S. Department of Justice and the Drug Enforcement Administration issued a final order immediately rescheduling FDA-approved marijuana drug products and state-licensed medical marijuana from Schedule I to Schedule III of the Controlled Substances Act. It is the most significant federal shift on marijuana classification in decades—and it has generated immediate questions from employers about what it means for their drug-free workplace policies.

The short answer: it changes less than headlines suggest, but more than employers can afford to ignore. The rescheduling does not legalize recreational marijuana at the federal level. It does not override DOT drug testing mandates. It does not require employers to permit on-the-job cannabis use. But it does affect policy language, accommodation analysis, and the broader trajectory of workplace drug testing.

Here is what employers need to understand now—and what steps to take before the next wave of changes arrives.

What the DOJ Order Actually Does

The April 23 order is narrower than many expected. It moves two specific categories of marijuana to Schedule III:

FDA-approved drug products containing marijuana (such as Epidiolex and any future FDA-approved formulations)
Marijuana manufactured, distributed, or dispensed under a qualifying state medical marijuana license

Recreational or adult-use marijuana—products not dispensed under a state medical license—remains Schedule I. Synthetic cannabinoids and products outside the state-licensed system are also unaffected.

The practical effect is that state-licensed medical marijuana dispensaries and manufacturers now have a legal pathway to register with the DEA, and IRS Section 280E—which previously blocked standard business deductions for cannabis companies—no longer applies to those entities.

For employers, the direct regulatory impact on drug testing is limited—but the indirect implications for policy are real.

What Has NOT Changed for Employers

Before adjusting anything, employers should understand what remains firmly in place:

Federal Workplace Drug Testing Requirements

The Mandatory Guidelines for Federal Workplace Drug Testing Programs, reaffirmed by HHS in March 2026, still include marijuana/THC on required testing panels. A positive THC result in a federally regulated test is still a positive—regardless of the employee's medical marijuana cardholder status.

DOT-Regulated Testing

The Department of Transportation has not modified its position: marijuana is prohibited for all safety-sensitive employees covered under 49 CFR Part 40. Medical Review Officers must continue to verify THC-positive results as positives. No prescription, state license, or medical marijuana card constitutes a legitimate medical explanation under DOT rules.

The Drug-Free Workplace Act

Federal contractors and grantees subject to the Drug-Free Workplace Act of 1988 must still certify that their workplaces are free from the unlawful manufacture, distribution, dispensation, possession, or use of controlled substances. While medical marijuana's reclassification to Schedule III technically removes it from the "unlawful" category in certain contexts, the Act's prohibitions remain intact for workplace conduct.

Employer Authority Over Workplace Conduct

Nothing in the DOJ order creates a new right for employees to use marijuana at work, arrive impaired, or refuse testing. Employers retain authority to prohibit impairment and to enforce workplace policies addressing substance use that affects job performance or safety.

What HAS Changed—and Why It Matters

Policy Language May Be Outdated

Many drug-free workplace policies reference marijuana as a "Schedule I controlled substance" or an "illegal drug under federal law." As of April 23, 2026, those descriptions are no longer fully accurate for state-licensed medical marijuana. Policies that rely on scheduling classification as the sole basis for prohibition may face legal challenges or confusion.

Action: Review policy language and replace scheduling-specific references with broader terms like "prohibited substances," "controlled substances that impair workplace performance," or a clearly enumerated list of substances covered by the policy.

Accommodation Requests Will Increase

The rescheduling gives employees and their attorneys a stronger foundation for accommodation arguments. If marijuana is no longer a Schedule I drug in the medical context, the argument that employers should treat medical marijuana more like a prescription medication becomes more credible—particularly in states that already protect medical marijuana patients in employment.

Over 20 states now have some form of employment protection for registered medical marijuana patients. States like California, Connecticut, and New York limit or prohibit adverse employment action based on off-duty marijuana use or a positive pre-employment test result.

Action: Update accommodation procedures to address medical marijuana requests. Document the interactive process. Distinguish between safety-sensitive and non-safety-sensitive roles. Consult legal counsel in each state where you have employees.

The "Impairment vs. Use" Distinction Matters More

With medical marijuana now Schedule III, employer policies that conflate off-duty use with on-the-job impairment face increasing scrutiny. THC metabolites can remain detectable for weeks after last use—long past any impairing effect. Employers that discipline solely based on a positive test result, without any evidence of impairment or a policy that clearly covers off-duty conduct, may face legal exposure in jurisdictions with employee protections.

Action: Consider whether your testing program and disciplinary framework adequately distinguish between evidence of use and evidence of impairment. Explore whether your policy addresses off-duty conduct explicitly and whether your state permits that approach.

What Employers Should Do Now

The DOJ order is final, but the regulatory landscape is still shifting. An expedited administrative hearing on broader rescheduling of recreational marijuana is scheduled to begin June 29, 2026. Additional guidance from SAMHSA, DOT, and state agencies is expected throughout the year.

Here is what employers should prioritize now:

1. Audit Your Policy Language

Pull out your drug-free workplace policy and review it for:

References to "Schedule I" substances or "illegal under federal law" as the basis for marijuana prohibition
Definitions of "controlled substances" that rely on scheduling classification alone
Outdated state law references
Language that fails to distinguish between on-duty and off-duty conduct

Replace outdated language with clear, affirmative statements about prohibited workplace conduct.

2. Map Your State Obligations

If you have employees in multiple states, create a compliance matrix that identifies:

Which states protect medical marijuana patients from adverse employment action
Which states restrict pre-employment marijuana testing
Which states have off-duty use protections
Which states allow exceptions for safety-sensitive positions or federal compliance

GovDocs maintains a state-by-state guide that tracks these protections.

3. Clarify Your Accommodation Process

Develop or update your procedure for handling accommodation requests related to medical marijuana. At minimum:

Identify who receives and evaluates the request
Document the interactive process
Distinguish safety-sensitive roles where accommodation may not be feasible
Consult legal counsel before denying or approving accommodations in states with explicit protections

4. Train Supervisors and HR Staff

Front-line managers and HR personnel need to understand:

The company's current policy and what it permits or prohibits
That the DOJ order does NOT mean employees can use marijuana at work
How to handle disclosure of medical marijuana cardholder status
When to escalate accommodation requests to legal or compliance teams
That DOT-regulated positions remain subject to strict federal rules

SAMHSA's employer resources continue to recommend supervisor training as a core component of an effective drug-free workplace program.

5. Monitor the June 2026 Hearing

The DEA's expedited hearing on broader rescheduling begins June 29, 2026. If recreational marijuana is also moved to Schedule III—or if Congress acts on federal legalization legislation—the employer landscape will shift further. Build a monitoring process now so you are not caught off guard.

How This Fits Into the Bigger Picture

The April 2026 rescheduling is not happening in isolation. It arrives alongside:

SAMHSA's addition of fentanyl to federal testing panels (effective July 2025), which expanded the mandatory screening requirements for federal employees
DOT's pending final rule on fentanyl for safety-sensitive transportation workers
Growing state-level restrictions on marijuana testing and employment action, now present in more than 20 states
Oral fluid testing standardization, which gives employers an additional specimen type for workplace testing

Together, these changes mean that drug-free workplace policies written even two or three years ago may already be out of step with the current legal framework. Employers that treat policy review as an annual compliance exercise—rather than a static document—will be better positioned to manage risk.

For employers looking to modernize their drug screening workflows while navigating these regulatory shifts, BlueHive's guide on 2025 Drug Screening Trends provides a practical overview of how testing methods, compliance requirements, and technology are evolving together.

The Bottom Line

The DOJ's marijuana rescheduling order is a landmark shift in federal drug policy—but it is not a green light for employers to abandon drug-free workplace programs. Federally regulated employers must maintain current testing and discipline protocols. Non-regulated employers retain broad authority to prohibit workplace impairment and to test employees consistent with state law.

What has changed is the ground beneath your policy language, your accommodation analysis, and your risk exposure in states with employment protections. The employers who act now—auditing policies, training supervisors, mapping state obligations, and monitoring the June hearing—will be far better prepared than those who wait for the next headline.